Share
[Editor’s note: This post has been updated to clarify that the meta-analysis published in Diabetologia and the Phase IIb trial were separate studies.] Earlier this fall, Phase IIb topline results of the DIAGNODE-2 trial demonstrated a potential type 1 diabetes vaccine GAD-alum — an immunomodulating antigen-specific therapy – had a highly significant and clinically relevant...
Share
For the sixth year running, Endocrine News talks to editors from Endocrine Society publications to get the scoop on the top endocrine discoveries of 2020. In this first installment, we talk to Endocrinology editors about what they think this year’s most significant studies were that will impact endocrine science for years to come. Despite the...
Share
Variants in genes that mediate fibroblast growth factor 21 – a hormone secreted by the liver that acts to regulate the body’s response to starvation – have for the first time been linked to severe insulin resistance, according to a paper recently published in the Journal of the Endocrine Society. Researchers led by Stephen Stone,...
Share
First study to utilize CGM data with FDA-cleared, cloud-based titration software suggests significantly improved outcomes for patients while optimizing clinical resources This past summer, Glytec published the first proof-of-concept study that combines FDA-cleared remote insulin titration software and data from continuous glucose monitoring (CGM) systems. Results of the study, presented at the American Diabetes Association’s...
Share
A clinical trial investigating a possible novel treatment of early-onset type 1 diabetes last month met the primary endpoint assessing the safety and tolerability of a new class of microbe-based therapeutic agents. Precigen ActoBio is evaluating this therapy — AG019 ActoBiotics — as a monotherapy and in combination with teplizumab. AG019 is formulated as an...
Share
About a third of men with type 2 diabetes (T2D) also have hypogonadotropic hypogonadism (HH). This comorbidity makes that subgroup more insulin resistant, with increased adiposity and less lean mass, according to research published recently in The Journal of Clinical Endocrinology & Metabolism. A team led by Paresh Dandona, BSc, MB, BS, DPhil, FRCP, of...
Share
The pleasure center of the brain and the brain’s biological clock are linked, and high-calorie foods — which bring pleasure — disrupt normal feeding schedules, resulting in overconsumption, according to a study recently published in Current Biology. Researchers led by Ali Güler, PhD, a professor of biology at the University of Virginia demonstrate that the...
Share
A drug used to treat type 2 diabetes could offer a simple and cheap solution to reduce dangerous side effects of steroid treatment, new research from Queen Mary University of London suggests. The phase 2 clinical trial, funded by Barts Charity, looked at the effects of the diabetes drug metformin on patients currently receiving high...
